Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Immvira Bioscience / Equity Capital Markets

<ul>
<li>ImmVira, a China-based clinical-stage biotech company, is seeking a Hong Kong Chapter 18A listing. Citigroup and CICC are the joint sponsors.</li>
<li>In our previous note, we looked at the company's core product MVR-T3011, including its mechanism and clinical data, as well as its management and investor backing.</li>
<li>In this note, we look at developments in the company's assets and the competitive setting.</li>
</ul>


ImmVira, a China-based clinical-stage biotech company, is seeking a Hong Kong Chapter 18A listing. Citigroup and CICC are the joint sponsors.
In our previous note, we looked at the company's core product MVR-T3011, including its mechanism and clinical data, as well as its management and investor backing.
In this note, we look at developments in the company's assets and the competitive setting.


ImmVira (亦诺微) Pre-IPO: Prospectus Update Suggests Stronger Bladder Data but a Higher Competitive Bar